Frost Radar：人工智慧驱动的临床试验，2026 年

Frost Radar: Artificial Intelligence-Enabled Clinical Trials, 2026

出版日期: 2026年01月12日 | 出版商:

Frost & Sullivan | 英文 59 Pages | 商品交期: 最快1-2个工作天内

价格

简介目录

标竿管理体系旨在鼓励企业行为创新，从而促进新业务的创建和成长。

人工智慧 (AI) 正在革新以技术驱动的药物发现和开发领域。在临床研究中，AI 的应用日益广泛，涵盖研究中心选择、研究设计和通讯协定优化，以及病患招募和管理。由于数据是药物发现和开发的核心，电子健康记录和真实世界数据也有助于支持研究结果并提高药物疗效。 AI 可以从各种非结构化资料中建立结构化资料库，从而简化资料评估并提高试验的安全性和效率。先进的生成式和基于代理的 AI 技术、真实世界数据以及协同驾驶的大规模语言模型，使得即时存取资料库成为可能，从而将合适的患者配对到合适的临床试验中。

利用人工智慧驱动的解决方案进行临床试验设计、中心选择、患者识别和保留，可以降低成本、提高效率，并透过远端患者招募、管理和互动，促进向分散式试验的过渡。互动式平台能够提高患者依从性并增强保留率。在本次Frost Radar分析中， Frost & Sullivan甄选出专注于创新人工智慧技术以支持临床试验以及产生和获取真实世界证据的公司，这些公司致力于解决高度成熟的临床试验行业面临的关键挑战。

Frost & Sullivan公司对产业内的众多公司进行分析。根据领导力及其他特征筛选出的公司将接受详细分析，并根据10项成长和创新标准进行基准测试，以确定其在Frost Radar上的位置。本刊物呈现了每家公司在Frost Radar上的竞争概况，并考虑了它们的优势以及最能发挥这些优势的机会。

Artificial intelligence (AI) has been revolutionizing the technology-enabled drug discovery and development landscape. In clinical research, AI has been gaining traction across site selection, trial design and protocol optimization, and patient recruitment and management. Because data is the core discipline of drug development, electronic medical records and real-world evidence also support trial outcomes and improve drug efficiency. AI can create structured databases from disparate and unstructured sources, simplifying data assessment and enhancing trial safety and efficiency. Sophisticated generative and agentic AI-based technologies and real-world data and copilot-based large language models provide real-time database access to target the right patient to the right clinical trial.

AI-driven solutions used in clinical trial design, site selection, and patient identification and retention can reduce costs, increase efficiency, and support the transition to decentralized trials by means of remote patient recruitment, management, and engagement. Interactive platforms ensure better patient adherence and greater retention. For this Frost Radar analysis, Frost & Sullivan selected companies that reflect a sharp focus on innovative AI technologies for clinical trial support and real-world evidence generation and access and a goal to overcome the key challenges across the highly mature clinical trials industry.

Frost & Sullivan analyzes numerous companies in an industry. Those selected for further analysis based on their leadership or other distinctions are benchmarked across 10 Growth and Innovation criteria to reveal their position on the Frost Radar. The publication presents competitive profiles of each company on the Frost Radar considering their strengths and the opportunities that best fit those strengths.